目前NAFLD药物治疗手段以针对代谢综 合 ... 专注 代谢性、病毒性疾病新药研发，NASH适应症布局FASN、THR-β以及FXR靶点，FASN抑制剂ASC40的临床2b数据发表 ...

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and is strongly associated with obesity, dyslipidaemia and altered glucose regulation. Previous ...

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are ...

Nat Clin Pract Gastroenterol Hepatol. 2009;6(1):18-19. Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the Western world. NAFLD is associated with chronic ...

FASN inhibitor treatment reduced atherosclerosis ... formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease ...

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors ... the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic ...

The presentation will focus on the differentiated mechanism of action of the FASN inhibitor denifanstat ... the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic ...

(Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b ...